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Abstract
Background: We report a case of a 53 year old lady recently commenced on etanercept, an anti-
TNF (tumour necrosis factor) therapy for rheumatoid arthritis presenting with confusion, pyrexia
and an erythematous rash.
Case presentation: A lumbar puncture was highly suggestive of bacterial meningitis, but CSF
cultures produced no growth, and polymerase chain reactions (PCR) for all previously reported
bacterial, fungal and viral causes of meningitis were negative.
Conclusion:  This case report describes aseptic meningitis as a previously unreported
complication of etanercept therapy, and serves as a reminder of the rare but potentially life-
threatening risk of serious infections in patients taking anti-TNF therapy for a variety of conditions.
Background
Etanercept functions as a soluble tumour necrosis factor
receptor, and is effective for the treatment of moderate to
severe rheumatoid arthritis [1]. It has also been licensed
for use in the treatment of juvenile idiopathic arthritis,
psoriatic arthritis, moderate to severe plaque psoriasis and
ankylosing spondylitis.
Due to its modulatory effect on the immune system, infec-
tions are a predictable potential complication of anti-TNF
therapy and patients are closely monitored. Rheumatoid
arthritis confers a higher baseline risk infections, and
when patients are treated with anti-TNF therapy, the
increased risk of infection has been extensively studied
and debated. Large cohort studies have shown an increase
in the rate of infection in patients on anti-TNF therapy
when compared to DMARDs alone [2,3], particularly
within the first six months of treatment, but this has not
been replicated in all randomised controlled studies and
observational cohort studies [4]. Re-activation of TB is a
potential side effect of anti-TNF therapy, although has
been reported more frequently with infliximab than
etanercept. Other reported serious side effects of etaner-
cept include reactivation of hepatitis B, demyelination
(new onset or exacerbation), pancytopenia and an
increased incidence of lymphoma.
Meningitis is a rare but potentially life threatening com-
plication which has been reported in patients treated with
anti-TNF therapy. Listeria monocytogenes infection is fre-
quently seen, and cases of meningitis secondary to this
agent have been reported in both infliximab and etaner-
cept therapy [5,6]. Other reported cases of meningitis
associated with etanercept have been secondary to tuber-
culosis, pneumococcus, varicella zoster and cryptococcus
[4,7-10]. Although there have been case reports of aseptic
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[11], viral, bacterial and fungal meningitis associated with
infliximab treatment, this case is the first in the literature
to our knowledge reporting aseptic meningitis in a patient
on etanercept.
Case presentation
A 53 year-old Caucasian lady was admitted to the Medical
Assessment Unit with a 4 day history of a spiking pyrexia,
a dry macular erythematous rash and a new onset of con-
fusion, generalised lethargy and difficulty sleeping.
Her past medical history included childhood rheumatic
fever, epilepsy (completely controlled on cam-
bamazepine), and rheumatoid arthritis, for which, 2
months previously, she had commenced weekly subcuta-
neous etanercept (50 mg), having failed to respond well
to methotrexate and hydroxychloroqine alone. She had
suffered a number of flare-ups in the proceeding 12
months, requiring 3 intramuscular steroid injections for
symptomatic control. On admission, she was also taking
tramadol, ibuprofen and 5 mg of folic acid. She is a full
time carer for her disabled husband, and smokes 4 ciga-
rettes daily.
Initial investigations revealed abnormal liver function
(ALT 204 iu/L, ALP 393 iu/L), a urine dipstick positive for
leucocytes and nitrites and a low white blood cell count of
3.9 × 109/L with raised inflammatory markers. She was
afebrile and haemodynamically stable with a normal
chest x-ray, and so was treated for a presumed urinary tract
infection with trimethoprim. An abdominal ultrasound
showed slight fatty hepatic infiltration, and urine cultures
gave mixed growth.
Over the next 3 days there was a general deterioration in
her condition, becoming increasingly confused with a
GCS of 12–13/15, and a pyrexia of up to 38.5°C. Despite
conversion of her antibiotics to intravenous amoxicillin,
her GCS fell to 10 and she became severely tachypnoeic
and peripherally shut down. With an evolving sepsis
apparent, she was fluid resuscitated and normal CT head
permitted a lumbar puncture. She was transferred to the
intensive care department for further management. The
CSF analysis showed a raised white cell count of 130/μL
(50% polymorphs), a glucose of 1.4 mmol/L and a pro-
tein of 1.02 g/L. This was highly suggestive of bacterial
meningitis, despite no meningism clinically, so she was
started on intravenous ceftriaxone and acyclovir (to cover
HSV encephalitis). Subsequent CSF culture revealed no
growth, and PCR was negative for cryptococcus, meningo-
coccus, listeria and common viral causes (HSV, VZV and
enterovirus). Her confusion and clinical parameters
improved and 3 days later she was transferred from ITU.
Although slight confusion persisted for some days, she
completed her course of IV antibiotics and was discharged
home after a further 10 days.
Discussion
This case highlights a very rare but serious complication of
a now commonly used medication, both within rheuma-
tology and increasingly elsewhere. Having failed to
achieve adequate disease control on non-biological ther-
apy, a difficult future management dilemma exists –
whether patients who have experienced serious infections
should be re-trialled on anti-TNF therapy, or whether the
risk of developing another life threatening complication
outweighs the potential benefit. This case also highlights
a previously unreported occurrence of aseptic meningitis
in a patient taking etanercept, and although this patient
had received antibiotics prior to the lumbar puncture
sample, CSF PCR for all previously reported bacterial
causes of meningitis in such patients was negative, sug-
gesting either a novel microbial agent or a true aseptic
meningitis.
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